Disclaimer upfront: Thymosin Alpha-1 (Tα1, brand name Zadaxin) is approved as a medicine in Italy, China, and over 35 other countries, mainly for chronic hepatitis B and C and primary immunodeficiency. In Germany, the EU outside Italy, and the United States it is not regularly approved. In the US it is used only off-label. In the EU outside Italy, the peptide is distributed almost exclusively as a research chemical. This article is a scientific overview, not a recommendation for self-administration. Any use belongs in the hands of a qualified physician.
TL;DR: Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced in the thymus, available synthetically since 1977. It modulates T cell maturation and acts bidirectionally — strengthens weak immune defense and dampens excessive reactions. Approved as Zadaxin in Italy and Asia, not in most of the EU or the US. Evidence for hepatitis B/C is solid, data on sepsis and COVID-19 come from observational studies.
What Thymosin Alpha-1 Is
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced in the thymus. The thymus is an organ behind the sternum that drives T lymphocyte maturation during childhood and adolescence. In adulthood, the thymus involutes and its function declines — a process linked to age-related weakening of the immune system.
In 1977, immunologist Allan Goldstein (George Washington University) first isolated and synthesized Tα1 from thymus extracts. The amino acid sequence is identical to the endogenous peptide, which distinguishes it pharmacologically from purely synthetic research peptides. The sequence reads: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn.
Brand name Zadaxin. The pharmaceutical form is marketed by SciClone Pharmaceuticals under the name Zadaxin. In Italy it has been approved as an adjuvant for hepatitis B since 1995, with further indications and countries added later. Regulatory status is the key distinction from other peptides in the biohacker scene: Tα1 has gone through approval studies, though not in every country.
For how Tα1 fits into the broader peptide landscape, see the peptides beginners guide.
Regulatory Status: Italy, US, EU, Asia
No other substance in this article series has such a complicated legal status. Anyone discussing Tα1 must differentiate between countries.
| Region | Status | Indications |
|---|---|---|
| Italy | approved | Hepatitis B/C (adjuvant), primary immunodeficiency |
| China, Taiwan, South Korea | approved | Hepatitis B/C, sepsis, immunodeficiency |
| Brazil, Argentina | approved | Hepatitis, immunodeficiency |
| 35+ other countries | approved | varies by country |
| US | not FDA-approved | off-label in compounding pharmacies |
| Germany, EU (outside Italy) | not approved | research chemical |
Italy is the regulatory outlier in the EU. Italian drug authority AIFA approved Zadaxin in 1995 as an adjuvant for chronic hepatitis B, later extended to hepatitis C and primary immunodeficiency. Italian doctors prescribe the peptide routinely, and costs are partially reimbursed.
United States. The FDA has never approved Zadaxin. Compounding pharmacies can prepare it on individual physician prescription, use remains off-label. The FDA 503A compounding list does not include Tα1, so legal status is ambiguous.
Germany and EU. Outside Italy, there is no regular approval. A medical single-import under §73 German drug law is theoretically possible when the active substance is approved in another EU country — in practice an import from Italy on physician prescription via a pharmacy with import permission. This is bureaucratic and rarely used.
Research chemical market. The bulk of non-medically supervised use in the EU and US runs through research chemical vendors. These products are not approved as medicines, and purity and identity are not guaranteed.
Mechanism of Action: Bidirectional Immune Modulation
Tα1 differs from classic immune stimulants through its bidirectional effect. The peptide binds to Toll-like receptors (mainly TLR-2 and TLR-9) on immune cells and modulates either upward or downward depending on immune status.
When immune defense is weak. Tα1 promotes maturation of immature T lymphocytes from the bone marrow into functional CD4 and CD8 T cells. It activates cytotoxic T cells that eliminate virus-infected and malignant cells. NK (natural killer) cell activity increases. Production of interferon-γ and interleukin-2 rises.
When the immune response is excessive. In extreme inflammatory situations such as sepsis or cytokine storm, Tα1 dampens the overactive immune reaction. It reduces release of proinflammatory cytokines like TNF-α and interleukin-6. This mechanism has been investigated most in sepsis and severe COVID-19.
T cell maturation. The central effect concerns thymic function. In adults with declining thymus activity, Tα1 can partially compensate for new T cell maturation. Studies in HIV patients and after chemotherapy show this effect most clearly.
The bidirectional action explains why Tα1 is investigated across such different clinical contexts — from hepatitis to sepsis.
Study Landscape: What Is Proven, What Remains Speculative
Evidence on Thymosin Alpha-1 is broad but varies widely in quality by indication. A structured overview:
Hepatitis B and C (approved indication)
The most solid data. Andreone et al. (2001) showed in a randomized trial that Tα1 combined with interferon-α in chronic hepatitis C achieves a higher sustained virological response than interferon alone. More recent Chinese work (Zhang et al. 2020) confirms effects in chronic hepatitis B, especially combined with standard antiviral therapies. These data underpin Italian and Asian approvals.
Sepsis
The ETASS study (Wu et al. 2013, 2015) in 361 septic patients in Chinese ICUs reported reduced 28-day mortality under Tα1 (26 percent vs. 35 percent in controls). A meta-analysis of several studies shows a consistent but moderate effect. In the EU, Tα1 is not approved for sepsis but is recommended in some Chinese guidelines.
COVID-19
Liu et al. (2020) published observational data from Wuhan on 76 severely ill COVID-19 patients. Mortality under Tα1 was 11 percent versus 30 percent without. Matteucci et al. (2021) reported similar trends in an Italian cohort. Both studies are retrospective, not randomized. Tα1 is nowhere officially approved for COVID-19, and WHO does not list it in its therapy guidelines.
Cancer adjuvant
Small studies on melanoma, liver, and lung cancer (mostly from China) combine Tα1 with chemotherapy and report improved quality of life and some survival benefit. Evidence is not sufficient for a Western approval decision.
Long COVID, Lyme, chronic fatigue
Data thin out here. Controlled human studies are almost entirely absent. Anecdotal reports and small case series circulate in the biohacker community without methodological basis for robust claims. Anyone using Tα1 for these indications is in experimental territory.
Dosing in the Context of Approved Use
Note: The following figures refer to approved use in Italy and Asia for hepatitis B/C. They are descriptive from Zadaxin’s prescribing information, not a dosing recommendation for self-administration.
The standard dose in chronic hepatitis is 1.6 mg subcutaneously twice weekly, with 3 to 4 days between doses. Therapy duration is 6 to 12 months depending on indication and response. For primary immunodeficiency and sepsis, studies use higher doses (up to 3.2 mg/day) always in inpatient settings.
Plasma half-life is about 2 hours, but the biological effect via immune cell modulation lasts much longer. That justifies twice-weekly dosing.
Lyophilisate and reconstitution. Zadaxin comes as a lyophilisate (freeze-dried powder) in a glass vial with a rubber septum. Before injection, the user reconstitutes the powder with sterile water. Injection is subcutaneous into abdominal or thigh tissue using a fine insulin needle. Approved use requires medical guidance, clean technique, and documentation.
Blood Value Monitoring During Therapeutic Use
Anyone using Tα1 under medical supervision needs a solid baseline and regular follow-up. Without these values, there is no way to judge whether the peptide helps or harms.
| Marker | Why it matters | Reference |
|---|---|---|
| Complete blood count with differential | Baseline immune status, lymphocyte dynamics | see CBC guide |
| Lymphocyte subsets (CD3, CD4, CD8) | Direct T cell effect of Tα1 | specialty lab |
| CD4/CD8 ratio | Immune balance, especially in HIV/immunodeficiency | 1.5–2.5 normal range |
| NK cells | Natural killer activity | 100–500 /µl |
| CRP, ESR | Inflammatory activity | CRP below 3 mg/l |
| ALT, AST, GGT | Liver function (relevant in hepatitis) | see blood values guide |
| Creatinine, eGFR | Kidney function, clearance | eGFR above 60 ml/min |
| ANA, rheumatoid factor | Autoimmune screen before therapy | negative |
| Hepatitis viral load | For hepatitis indication | quantitative |
More on inflammation diagnostics in the inflammation markers guide. Document before start, repeat at 4 weeks, 3 months, and quarterly for longer use.
Distinction from Thymosin β4 (TB-500) and Other Thymus Peptides
A common mistake in the peptide community: Thymosin Alpha-1 and Thymosin β4 are equated because both carry thymosin in their name. That is wrong.
| Property | Thymosin Alpha-1 (Tα1) | Thymosin β4 (TB-500) |
|---|---|---|
| Amino acids | 28 | 43 (TB-500: 17-aa fragment) |
| Mechanism | Immune modulation via TLR receptors | Actin binding, cell migration |
| Approval | Italy, Asia (Zadaxin) | nowhere as medicine |
| Indication | Hepatitis, immunodeficiency | no approved indication |
| WADA 2026 | not explicitly banned | banned since 2022 |
| Target domain | Immune system | Tissue repair, wound healing |
The common element ends with the name component thymosin, which stems from the original isolation from thymus extracts. Biologically and clinically the two peptides are completely different substances with different target molecules. Anyone considering Tα1 should check protocols and studies specifically for the right peptide.
Contraindications and Risks
Tα1 is considered well tolerated in approval studies. Some situations are clear contraindications or require special caution.
Active autoimmune disease. Rheumatoid arthritis, lupus, multiple sclerosis, active Hashimoto flares. Immune stimulation can intensify autoimmune inflammation. An autoimmune screen (ANA, rheumatoid factor, specific antibodies as needed) is mandatory before therapy.
After organ transplantation. Tα1 is contraindicated here. Transplant patients need permanent immunosuppression to prevent rejection. Immune stimulation works in the opposite direction and may endanger the graft.
Pregnancy and breastfeeding. Insufficient data. Do not use without compelling medical indication.
Allergic reactions. Very rare but possible. Discontinue if hypersensitivity to ingredients is known.
Injection risks. Abscesses, infections from unsterile technique. Not specific to Tα1 — applies to any subcutaneous injection.
Quality risks with research chemical sourcing. Without certificate of analysis (COA) and GMP certification, purity and identity are not guaranteed. A significant share of grey market products contain less active substance than declared or contaminants. Detailed quality criteria are in the BPC-157 analysis.
Practical Perspective
Thymosin Alpha-1 is one of the few peptides in biohacker discussion with an actual regulatory anchor — Italian and Asian approval. That distinguishes it from BPC-157, Epithalon, or Selank, which are not approved as medicines anywhere.
Three situations where considering Tα1 makes sense at all:
- Chronic hepatitis B or C under hepatology supervision when standard therapies are insufficient and single-import from Italy is an option.
- Primary immunodeficiency with clear diagnosis and immunological care.
- Chronic viral or recurrent infections in the context of comprehensive medical evaluation, not as first-line option.
For everything else — anti-aging, performance enhancement, nonspecific fatigue — evidence is lacking. Those who experiment anyway do so in legal and medical grey zones.
For a structured baseline before any peptide consideration, see the biomarker baseline checklist. The peptides beginners guide places Tα1 in the broader peptide landscape.
Conclusion: Approved in Italy, Grey Zone Elsewhere
Thymosin Alpha-1 is a well-researched peptide with solid approval in Italy, China, and over 35 other countries for clearly defined indications. Bidirectional immune modulation makes it clinically interesting — solid evidence for hepatitis and sepsis, insufficient for COVID-19 and cancer adjuvant.
Three takeaways:
- Regulatory reality. Not regularly approved in most of the EU or in the US. A single-import from Italy is possible for approved indications but bureaucratic.
- Difference from TB-500. Thymosin Alpha-1 and Thymosin β4 are completely different peptides. Name similarity is misleading.
- Monitoring is mandatory. Complete blood count, lymphocyte subsets, liver/kidney values, autoimmune screen as baseline. No therapy without baseline.
For digital tracking of blood values, the Lab2go features provide the right tools. The pricing overview shows tier options for detailed biomarker tracking.
This article does not replace medical advice. Thymosin Alpha-1 is not regularly approved as a medicine in Germany, most of the EU, or the US. Human use outside approved indications is legally problematic. Every therapy decision belongs in medical hands — self-medication with unapproved peptides carries health and legal risks.
Article FAQ
- Is Thymosin Alpha-1 legal in the EU and US?
- No, Thymosin Alpha-1 (brand name Zadaxin) is not approved as a medicine in Germany, most of the EU, or the US. It is approved in Italy, China, and over 35 other countries for hepatitis B and C and primary immunodeficiency. In the EU outside Italy and in the US, it is distributed almost exclusively as a research chemical. Human use without medical supervision is legally problematic. A prescription import from Italy under EU pharmaceutical regulations is possible in individual cases with a specialist physician.
- What is the difference between Thymosin Alpha-1 and TB-500?
- Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide that modulates T cell and NK cell maturation. TB-500 is a synthetic fragment of Thymosin β4 and works through actin binding on cell migration and tissue repair. Both carry thymosin in their name but have completely different mechanisms of action. Tα1 is approved in some countries as an immunomodulator, TB-500 nowhere. Equating them is a common mistake in the peptide community.
- How does Thymosin Alpha-1 work?
- Tα1 acts bidirectionally on the immune system. When immune defense is weak, it stimulates T cell maturation, activates cytotoxic T cells and NK cells, and increases cytokine production. When the immune response is excessive, as in sepsis storm, it dampens the inflammatory cascade. This balancing effect via Toll-like receptors TLR-2 and TLR-9 distinguishes Tα1 from simple immune stimulants. The peptide is not directly antiviral but strengthens the body's own defense.
- For which indications is Zadaxin approved?
- Zadaxin (Thymosin Alpha-1) is approved in Italy, China, Brazil, and over 35 other countries as an adjuvant for chronic hepatitis B and C. In some countries also as a vaccine booster in immunosuppressed patients and to treat primary immunodeficiency. The standard dose in hepatitis is 1.6 mg subcutaneously twice weekly for 6 to 12 months. In the EU outside Italy and in the US, Zadaxin is not regularly approved.
- Which blood values should be monitored during Thymosin Alpha-1 therapy?
- Before and during a medically supervised Tα1 therapy, the lab panel includes complete blood count with differential, ideally lymphocyte subsets (CD3, CD4, CD8, CD4/CD8 ratio, NK cells), CRP, liver enzymes (ALT, AST, GGT), and kidney values (creatinine, eGFR). For hepatitis indications, add viral load and liver fibrosis markers. An autoimmune screen (ANA, rheumatoid factor) makes sense because immune stimulation can trigger flares in latent autoimmune disease.
- Are there studies on Thymosin Alpha-1 in COVID-19?
- Yes, Chinese observational studies (Liu et al. 2020, Wuhan) reported reduced mortality in severely ill COVID-19 patients given Tα1. An Italian retrospective cohort (Matteucci et al. 2021) showed similar trends. These data come from observational studies without randomization. Tα1 is not officially approved anywhere for COVID-19. The World Health Organization does not list the peptide in its therapy guidelines. Evidence quality is not sufficient for a standard recommendation.
- What side effects are described?
- In hepatitis approval studies, Thymosin Alpha-1 is well tolerated. The most common side effect is a local reaction at the injection site (redness, tenderness) in about 5 to 10 percent of users. Systemic side effects like mild fever, muscle pain, or fatigue are rare. Active autoimmune diseases are critical because immune stimulation can trigger flares. Tα1 is contraindicated after organ transplantation because the required immunosuppression acts in the opposite direction.
- Can Thymosin Alpha-1 help with Long COVID or chronic fatigue?
- For Long COVID, Lyme disease, and chronic fatigue syndrome (CFS/ME), there are no controlled human studies with Thymosin Alpha-1. Anecdotal reports and small case series exist in the biohacker community, but evidence is thin. As long as these indications are not approved and not backed by randomized studies, use remains experimental. Medically supervised, documented therapy with baseline blood values is the minimum standard.
- How is Thymosin Alpha-1 administered?
- The approved administration route is subcutaneous injection. The standard dose in hepatitis B/C is 1.6 mg twice weekly, ideally with 3 to 4 days between doses. The peptide is delivered as a lyophilisate (freeze-dried powder) that is reconstituted with sterile water and injected into subcutaneous tissue on the abdomen or thigh using a fine insulin needle. Oral or nasal forms are not established or approved. Plasma half-life is about 2 hours, but the biological effect lasts significantly longer.
- Is Thymosin Alpha-1 on the WADA prohibited list?
- As of 2026, Thymosin Alpha-1 is not explicitly on the WADA prohibited list, unlike BPC-157 or Thymosin β4, which have been banned since 2022. However, since Tα1 is not approved as a medicine in most WADA jurisdictions, it could fall under Category S0 (non-approved substances) when used without medical indication. Competitive athletes should check with anti-doping advisors before any use, as the list changes annually.
Discussion
Community comments coming soon. Until then, we welcome feedback and questions via email.
E-Mail anzeigen
